Navigation Links
2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
Date:7/21/2011

NEW YORK, July 21, 2011 /PRNewswire/ -- Honoring biomedical advances impacting both individual lives and public health in the past decade, the Prix Galien USA committee today announced the 2011 final candidates for the 5th annual Prix Galien Awards competition. The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices, and is considered the industry's highest accolade.

Final candidates for the Prix Galien USA 2011 Awards are: Amgen (Prolia®)Janssen Biotech Inc. (Stelara™) Boehringer Ingelheim (Pradaxa®)Merck (Emend®)Cubist (Cubicin®) Merck (Zetia®)Dendreon (Provenge®)Novartis (Gilenya®) Eisai (Banzel®)Pfizer (Prevnar 13®)GlaxoSmithKline (Arzerra™)"Pharmaceutical research and development advances the human condition through the development of novel therapies and cures," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal. "This year's candidates demonstrate the positive impact biomedical discovery and innovation can have on improving lives of individuals."

As in past years, the committee will judge candidates as Best Pharmaceutical Agent and Best Biotechnology Product approved by the U.S. Food and Drug Administration (FDA) during the past 10 years.

"Prix Galien salutes the major contributions of the scientists and researchers who devote their lives to the development of treatments in the continuous quest to improve the health of the world's population," said Elie Wiesel, Nobel Laureate and Prix Galien USA committee member.

2011 candidates range from a vaccine to protect babies from seven strains of pneumococcal bacteria to the first oral drug therapy for relapsing forms of multiple sclerosis.  In 2010, the Prix Galien USA committee honored life sciences companies for innovations such as therapies for rare genetic disorders and diagnostic tests to indentify infections.  Last year's honorees include Luminex Corporation (xTAG ®), Novartis (Coartem®) and Merck & Co. (RotaTeq®).

The Award Ceremony, held at the Museum of Natural History in New York City, September 27, 2011, is among the most prestigious prizes for biopharmaceutical research and development.  The Prix Galien USA award committee comprises 11 individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.  Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007.

For details about the Prix Galien - USA award and committee, visit www.galienfoundation.org

AWARDS COMMITTEE

MICHAEL S. BROWN, M.D.*
UT Southwestern Medical Center at Dallas

WALTER GILBERT, PH.D.*
Harvard University

JOSEPH GOLDSTEIN, M.D.*
UT Southwestern Medical Center at Dallas

PAUL GREENGARD, PH.D.*
Rockefeller University

ERIC R. KANDEL, M.D.*
Columbia University

RICHARD A. LERNER, M.D.
Scripps Research Institute

PAUL A. MARKS, M.D.
Memorial Sloan Kettering Cancer Center

BENGT SAMUELSSON, M.D., PH.D.*
Nobel Foundation, Karolinska Institute

JAN T. VILCEK, M.D.
New York University School of Medicine

ELIE WIESEL*
Honorary Member, Boston University

GERALD WEISSMANN, M.D.
New York University School of Medicine Committee Chairman

*Nobel Laureate

The Galien Foundation is a not-for-profit, 501(c)(3) public charity. Contributions are tax deductible as provided by law.

CONTACT:  Mary Heather, Porter Novelli for Prix Galien USA, +1-212-601-8153


'/>"/>

SOURCE Prix Galien USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Porter Novelli Named Agency of Record for Prix Galien USA Awards
2. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
3. 2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort
4. Prix Galien USA Honors Innovation in Science and Biotech Industries
5. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
6. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
7. Next-Generation Pharmacist™ Awards Program Announces 2011 Finalists
8. Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award
9. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
10. Millennium Laboratories Founder and CEO James Slattery Named Ernst & Young Entrepreneur of the Year® San Diego Finalist
11. CardioMEMS Founder & CEO Dr. Jay Yadav Named Ernst & Young Entrepreneur of the Year Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):